Growth Disorders
We recommend
Somapacitan administered once weekly in the treatment of children with growth hormone deficiency – current understanding
Somapacitan is a long-acting derivative of recombinant human growth hormone approved for the treatment of children and adults with growth hormone (GH) deficiency. Dr. Reiko Horikawa from Japan's National Center for Child Health and Development in Tokyo, during the 24th Pediatric Endocrinology Days held in Brno in January 2024, showed that it is a promising therapeutic option for pediatric patients from 3 years of age, thanks to its efficacy, safety, and potential to improve therapy adherence. However, careful long-term monitoring of the…
Cardiovascular System Affection in Children with Noonan Syndrome
Noonan syndrome is a genetically conditioned disease classified among the so-called RASopathies,…
Prenatal Phenotype of Children with Noonan Syndrome
Until recently, the various phenotypes of RASopathies were clinically diagnosed only after birth.…
Articles on this topic
Noonan Syndrome (Not Just) in the Pediatric Cardiologist's Office
Noonan Syndrome (NS) is a genetically determined disease associated with a high prevalence of…
Noonan's Syndrome – History and Present
The genetically determined syndrome linking congenital heart defect with a typical facial…
Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care
Treatment with recombinant growth hormone (rhGH) is available in the Czech Republic for all…
Most read on this topic
Related topic
- Prenatal diagnosis of Noonan syndrome in fetuses with increased nuchal translucency and a normal karyotype
- Noonan's Syndrome – History and Present
- Noonan Syndrome (Not Just) in the Pediatric Cardiologist's Office
- Cardiovascular System Affection in Children with Noonan Syndrome
- Prenatal Phenotype of Children with Noonan Syndrome
- Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care
Related topic